NSE GLENMARK · BSE 532296 · Biotechnology & Drugs · NIFTY 500

Glenmark Pharmaceuticals Share Price

Market closed · NSE price as of Thu 24 Sep, 8:25 AM IST
₹2,434.20 ▼ −₹44.11 · 1.78%
Day range · 24 Sep
₹2,424.10Low₹2,472.10High
52-week range
₹1,794.00Low · 28 Oct 2025₹2,536.85High · 28 Aug 2026

Glenmark Pharmaceuticals Overview

Where the price stands, how it has moved and how it sits against its averages.

Glenmark Pharmaceuticals shares last traded at ₹2,434.20 on the NSE, down 1.78% on the day. That is 4.0% below the 52-week high of ₹2,536.85 and 35.7% above the 52-week low of ₹1,794.00. The stock trades at 38.11× earnings, above the sector average of 36.50. Its market value is ₹68,524 Cr.

Price returns

1 Day▼ −1.78%
1 Week0.00%
This month▼ −0.20%
3 Months▲ +13.50%
6 Months▲ +14.13%
This year▲ +21.61%
1 Year▲ +22.72%

Against the market: 1 Month ▲ +5.09% · 3 Months ▲ +16.78% · 6 Months ▲ +14.81% · This year ▲ +38.50% · 1 Year ▲ +34.65%

Shading grows with the size of the move. We ask our data provider for a newer price every 15 minutes while the market is open (9:15 AM–3:30 PM IST); next check from Fri 16 Oct, 9:15 AM. Its quotes are not real-time — the time at the top shows how current the price is.

Moving averages — price is above 4 of 6

  1. 20-day average₹2,440.54 ▼ price 0.3% below
  2. 5-day average₹2,436.96 ▼ price 0.1% below
  3. Today's price₹2,434.20
  4. 10-day average₹2,430.02 ▲ price 0.2% above
  5. 50-day average₹2,332.64 ▲ price 4.4% above
  6. 100-day average₹2,296.02 ▲ price 6.0% above
  7. 300-day average₹2,180.43 ▲ price 11.6% above

Each average is the mean closing price over that many trading days; averages above the current price sit higher on the ladder.

Glenmark Pharmaceuticals Financial Results

Revenue and net profit in ₹ crore, with the full statements underneath.

Revenue₹ crore
16,983
Net profit₹ crore · losses below zero
−1,502
1,362

Year by year

Fiscal yearRevenueGrowthNet profitNet marginEPSDividend
FY 2026 ₹16,983 Cr ▲ +27.5% ₹1,362 Cr 8.0% ₹48.24 ₹5.00
FY 2025 ₹13,322 Cr ▲ +12.8% ₹1,047 Cr 7.9% ₹37.10 ₹2.50
FY 2024 ₹11,813 Cr ▲ +2.0% −₹1,502 Cr −12.7% −₹67.30 ₹2.50
FY 2023 ₹11,583 Cr ▼ −5.9% ₹297 Cr 2.6% −₹6.01 ₹2.50
FY 2022 ₹12,305 Cr ▲ +12.4% ₹942 Cr 7.7% ₹33.37 ₹2.50
FY 2021 ₹10,944 Cr ▲ +2.8% ₹970 Cr 8.9% ₹34.38 ₹2.50
FY 2020 ₹10,641 Cr — ₹776 Cr 7.3% ₹27.50 ₹2.50

Balance sheet — FY26

Owes (liabilities)Shareholders' equity
47%
53%
  • Total assets₹19,908 Cr
  • Total liabilities₹9,396 Cr
  • Shareholders' equity₹10,512 Cr
  • Total debt₹594 Cr
  • Cash & investments₹1,175 Cr
  • Current ratio1.77×
  • Revenue growth, 5 yr9.19% a year
  • EPS growth, 5 yr7.01% a year
  • Operating margin (TTM)12.61%
  • Net margin (TTM)10.14%

Cash flow — FY26

Operating activities
▲ ₹3,445 Cr
Investing activities
▼ −₹1,283 Cr
Financing activities
▼ −₹2,709 Cr
Free cash flow
▲ ₹2,087 Cr
Net change in cash
▼ −₹501 Cr

Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.

Full financial statements, FY20–FY26
₹ croreFY20FY21FY22FY23FY24FY25FY26
Total revenue10,640.9710,943.9312,304.9011,583.2411,813.1013,321.7416,982.51
Cost of revenue4,208.754,327.184,978.814,698.355,003.044,888.745,248.03
Gross profit6,432.226,616.757,326.096,884.886,810.068,433.0011,734.48
Operating expenses9,326.009,258.5610,725.7711,283.2612,100.6311,829.1915,245.39
Operating income1,314.971,685.371,579.14299.98−287.531,492.551,737.12
Depreciation417.17443.55486.72569.17581.91486.01573.48
Profit before tax1,096.081,382.481,441.25239.8436.501,399.211,984.75
Tax320.11412.39447.60329.401,867.35352.07622.79
Net profit775.97970.09941.71297.25−1,501.671,047.101,361.85
EPS (₹)27.5034.3833.37−6.01−67.3037.1048.24
Dividend per share (₹)2.502.502.502.502.502.505.00

Glenmark Pharmaceuticals vs Peers

Side by side with other biotechnology & drugs companies. The small bars compare each column.

CompanyPriceChangeMarket capP/EP/BROE (5 yr)Net marginDiv. yield
Glenmark Pharmaceuticals This stock ₹2,434.20 ▼ −1.78% ₹68,524 Cr 38.11 6.53 2.91% 10.14% 0.21%
Sun Pharmaceutical Industries ₹1,852.20 ▼ −0.69% ₹4,44,394 Cr 38.40 5.55 14.22% 19.12% 0.83%
Divi's Laboratories ₹9,617.50 ▲ +0.22% ₹2,55,314 Cr 73.32 11.48 16.87% 24.32% 0.41%
Torrent Pharmaceuticals ₹4,925.85 ▼ −1.09% ₹1,87,357 Cr 72.73 19.22 23.00% 15.29% 0.80%
Cipla ₹1,398.00 ▲ +1.30% ₹1,12,939 Cr 27.57 3.33 14.47% 13.74% 0.92%
Zydus Lifesciences ₹1,175.00 ▲ +0.47% ₹1,17,207 Cr 21.19 4.24 17.90% 18.51% 0.09%

Peer prices and ratios as last reported by the data provider. Company names link to their own pages.

Shareholding Pattern

Who owns Glenmark Pharmaceuticals shares, quarter by quarter (latest on top).

PromoterFIIMFOther
Jun '26
46.7%
20.9%
16.8%
15.7%
Mar '26
Dec '25
Sep '25
HolderSep '25Dec '25Mar '26Jun '26Change
Promoter46.65%46.65%46.65%46.65% 0.00 pts
FII20.73%19.20%20.35%20.89% ▲ +0.54 pts
MF16.31%17.86%16.80%16.76% ▼ −0.04 pts
Other16.31%16.29%16.20%15.70% ▼ −0.50 pts

Glenmark Pharmaceuticals Key Metrics

Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.

Glenmark PharmaceuticalsBenchmarkRule-of-thumb bands

Valuation The price against earnings, book value and sales

P/E (TTM)Price ÷ yearly earnings per share
38.11
▲ 4% above the sector average of 36.50
P/E, 12-month rangeLow 13.25 · high 65.67
47%
Today's P/E sits 47% of the way from its low to its high
P/BPrice ÷ book value per share
6.53
P/SMarket cap ÷ last 12 months' revenue
3.86
P/CFPrice ÷ cash flow per share
28.93
PEGP/E ÷ earnings growth rate
5.54

Profitability Of every ₹100 of sales, how much is kept?

Gross marginKept after the cost of goods
71.94%
▲ above its 5-yr average of 62.40%
Operating marginKept after running costs
12.61%
▲ above its 5-yr average of 7.30%
Pre-tax marginKept before tax
14.28%
▲ above its 5-yr average of 7.73%
Net marginKept as profit
10.14%
▲ above its 5-yr average of 2.25%

Returns & efficiency How well does it use its money?

Return on equityProfit on shareholders' money
14.07%
▲ above its 5-yr average of 2.91%
Return on assetsProfit on everything it owns
7.58%
▲ above its 5-yr average of 1.75%
Return on investmentProfit on long-term capital
11.53%
▲ above its 5-yr average of 2.57%
Return on capital employedProfit before interest and tax on equity + debt
17.70%

Growth Is the business getting bigger?

Revenue — last 12 months
+32.9%
▲ growing (off the scale)
Revenue — 3 yr, a year
+13.6%
▲ growing
Revenue — 5 yr, a year
+9.2%
▲ growing
Net profit — 3 yr, a year
+66.1%
▲ growing (off the scale)
Net profit — 5 yr, a year
+7.0%
▲ growing
EPS — last 12 months
+138.5%
▲ growing (off the scale)
EPS — 5 yr, a year
+7.0%
▲ growing
Dividend — 3 yr, a year
+26.0%
▲ growing (off the scale)
Book value — 5 yr, a year
+8.3%
▲ growing

Financial strength Can it pay its bills and debts?

Debt to equityBorrowings for every ₹1 of shareholders' money
0.06×
✓ Low debt
Current ratioShort-term assets for every ₹1 due within a year
1.77×
✓ Comfortable
Quick ratioLike the current ratio, without inventory
1.17×
✓ Comfortable
Interest coverOperating profit ÷ interest to pay
20.44×
✓ Strong
Payout ratioShare of profit paid as dividend
10.36%
• Keeps most

Per share What each share stands for

EPS (TTM)
₹63.68
Book value
₹372.51
Cash flow
₹85.52
Dividend
₹5.00
Revenue
₹628.23

The share price is 6.53× the book value behind each share.

Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.

All 110 metrics from the data provider

Valuation

P/E excluding extraordinary items, most recent fiscal year51.30
Current Dividend Yield - Common Stock Primary Issue, LTM0.20
Price to Book - most recent fiscal year6.64
P/E Basic excluding extraordinary items - TTM34.60
P/E including extraordinary items - TTM38.86
P/E excluding extraordinary items low, trailing 12 months13.25
Price to Tangible Book - most fiscal year8.72
Dividend Yield - 5 Year Average0.27
Price to sales - most recent fiscal year4.11
Dividend Yield - indicated annual dividend divided by closing price0.20
Price to Cash Flow per share - trailing 12 month28.93
Peg Ratio5.54
Price to Free Cash Flow per Share - most recent fiscal year35.89
P/E Normalized, most recent fiscal year23.95
P/E excluding extraordinary items high, trailing 12 months65.67
P/E excluding extraordinary items, most recent fiscal year quarter38.86
Price to sales - trailing 12 month3.94
Net Debt, LFY−5,811.82

Per share

Dividend Per Share - 5 year average3.00
Cash Flow per share - trailing 12 month85.52
Cash Flow per share - most recent fiscal year68.56
EPS including extraordinary items - trailing 12 month63.68
EPS including extraordinary items - most recent fiscal year48.24
EBITD per share - trailing 12 month169.90
Revenue/share - trailing 12 month628.23
EPS excluding extraordinary items - trailing 12 month63.68
EPS Basic excluding extraordinary items - most recent fiscal year48.26
EPS Basic excluding extraordinary items - trailing 12 month63.71
Book value per share - most recent fiscal year372.50
Dividend per share - most recent fiscal year5.00
Revenue/share - most recent fiscal year601.60
EPS Normalized - most recent fiscal year103.33
Book value (tangible) per share - most recent fiscal year283.69
Dividends per share - trailing 12 month5.00
EPS excluding extraordinary items - most recent fiscal year48.24
Cash per share - most recent fiscal year41.63

Margins

Operating margin - trailing 12 month12.61
Gross Margin - 5 year average62.40
Operating margin - 1st historical fiscal year10.23
Operating Margin - 5 year average7.30
Net Profit Margin % - 1st historical fiscal year8.02
Gross Margin - 1st historical fiscal year69.10
Net Profit Margin % - trailing 12 month10.14
Net Profit Margin - 5 year average2.25
Pretax Margin - 5 year average7.73
Pretax margin - 1st historical fiscal year11.69
Pretax margin - trailing 12 month14.28
Free Operating Cash Flow/Revenue, 5 Year Average−1.64
Gross Margin - trailing 12 month71.94

Growth

EPS Change %, TTM over TTM138.47
Revenue growth rate, 5 year9.19
EPS growth rate, 5 year7.01
Revenue Change % - most recent quarter 1 year ago23.10
Growth rate% - dividend, 3 year25.99
Revenue/share (5 yr growth)9.18
Free Operating Cash Flow, 5 Year CAGR46.75
Tangible Book Value, Total Equity, 5 Year CAGR11.10
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year Interim CAGR17.09
Capital Spending growth rate, 5 year11.87
Revenue Change %, TTM over TTM32.94
Growth rate% - Revenue, 3 year13.60
Book value per share growth rate, 5 year8.27
EPS Change % - most recent quarter 1 year ago930.72
Net Profit Margin growth rate, 5 year−1.98
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR17.03
Total Debt, 5 Year CAGR−34.67

Financial strength

Free Cash Flow - most recent fiscal year19,462.91
LT debt/equity - most recent fiscal year0.05
Quick ratio - most recent fiscal year1.17
Payout ratio - trailing 12 month7.85
Current ratio - most recent fiscal year1.77
Current EV/Free Cash Flow, LFY158.62
Total debt/total equity - most recent fiscal year0.06
Net Interest coverage - trailing 12 month20.44
Payout ratio - most recent fiscal year10.36

Returns & efficiency

Return on average equity - 5 year average2.91
Net Income/employee - trailing 12 month12,54,751.00
Revenue/employee - most recent fiscal year1,22,15,440.00
Return on investment - most recent fiscal year11.53
Return on average assets - most recent fiscal year7.58
Receivables turnover - most recent fiscal year4.09
Inventory turnover - most recent fiscal year1.48
Revenue/employee - trailing 12 month1,23,78,950.00
Return on average assets - 5 year average1.75
Net Income/employee - most recent fiscal year9,79,645.40
Asset turnover - most recent fiscal year0.94
Return on average equity - most recent fiscal year14.07
Return on investment - 5 year average2.57

Price & volume

Market Cap68,481.81
52 week Low Date28 Oct 2025
Price - 1 Day % Change0.55
Relative (S&P500) price percent change - 13 week16.78
Avg trading volume last 10 days0.42
Price - 13 week price percent change13.50
Price - 52 week price percent change22.72
Avg Trading Volume Last 3 months11.16
Price - 5 Day % Change2.70
Price % Change Month To Date−0.20
Relative (S&P500) price percent change - 04 week5.09
52 week High Date28 Aug 2026
Price - 26 week price percent change14.13
PDATE23 Sep 2026
Price - YTD price percent change21.61
Relative (S&P500) price percent change - 52 week34.65
NPRICE2,475.00
Relative (S&P500) price percent change - 26 week14.81
52 week Low1,792.60
52 week High2,537.60
Beta0.81
Relative (S&P500) price percent change - Year to Date38.50

Dividends & Corporate Events

Payouts to shareholders, splits and bonus issues, and company meetings — newest first.

Dividend per share₹ per share, by fiscal year
₹5.00
  • Dividend yield0.21%
  • Payout ratio10.36%
  • 5-year average dividend₹3.00 a share
  • Latest dividend₹2.50 per share · 31 Aug 2026

Corporate calendar

  • MeetingAnnual General Meeting
  • Dividend₹2.50 per share · 250% · Final dividend
  • BoardQuarterly Results
  • BoardAudited Results & Final Dividend
  • BoardQuarterly Results
  • BoardQuarterly Results
  • Dividend₹2.50 per share · 250% · Interim dividend
  • MeetingAnnual General Meeting
Show 13 older events
  • BoardInterim Dividend
  • Dividend₹2.50 per share · 250% · Final dividend
  • BoardQuarterly Results
  • MeetingPostal Ballot
  • BoardAudited Results & Final Dividend
  • MeetingPostal Ballot
  • BoardQuarterly Results
  • MeetingAnnual General Meeting
  • Dividend₹2.50 per share · 250% · Final dividend
  • MeetingPostal Ballot
  • Dividend₹2.50 per share · 250% · Final dividend
  • Dividend₹2.50 per share · 250% · Final dividend
  • Dividend₹2.50 per share · 250% · Final dividend

About Glenmark Pharmaceuticals

Biotechnology & Drugs

Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.

Key people

  • Glenn Mario SaldanhaExecutive Chairman of the Board, Managing Director
  • Anurag MantriGlobal Chief Financial Officer, Executive Director
  • Rashmi KhandelwalCompliance Officer, Company Secretary
  • Cherylann PintoExecutive Director - Corporate Services

Company facts

  • NSE symbolGLENMARK
  • BSE code532296
  • ISININE935A01035
  • IndustryBiotechnology & Drugs
  • IndexNIFTY 500
  • Market cap₹68,524 Cr
  • Revenue (FY26)₹16,983 Cr
  • Net profit (FY26)₹1,362 Cr

In the News

Recent headlines about Glenmark Pharmaceuticals — they open on Mint in a new tab.

Stock data comes from the exchange feed via our data provider. It is not real-time and can be delayed, so check the price with your broker before you trade. This page is for information and education only. It is not investment advice, research or a recommendation to buy, sell or hold any security. Investments in the securities market are subject to market risks; read all related documents carefully before investing. See all stocks →

Frequently Asked Questions

Glenmark Pharmaceuticals (NSE: GLENMARK) last traded at ₹2,434.20 on the NSE, down 1.78% (₹44.11) on the day, as of 24 Sep 2026, 8:25 AM IST. On the BSE it was ₹2,428.00. The day's range was ₹2,424.10 – ₹2,472.10.

Glenmark Pharmaceuticals's 52-week high is ₹2,536.85 (28 Aug 2026) and its 52-week low is ₹1,794.00 (28 Oct 2025). At ₹2,434.20 the share is 4.0% below its high and 35.7% above its low.

Glenmark Pharmaceuticals's market capitalisation is ₹68,524 Cr (₹68,524 Cr). It is part of the NIFTY 500 index.

Glenmark Pharmaceuticals's P/E ratio (trailing 12 months) is 38.11. The sector average is 36.50, so investors pay 4% more for each rupee of its earnings than for the average company in its sector. Its earnings per share (TTM) are ₹63.68.

Glenmark Pharmaceuticals shares are up 22.72% over the last year, up 21.61% so far this year, up 14.13% over 6 months, up 13.50% over 3 months. Over the last year the stock did 34.65% better than the market.

In FY26 (year to Mar 2026), Glenmark Pharmaceuticals reported revenue of ₹16,983 Cr (up 27.48% on the year before) and a net profit of ₹1,362 Cr. Earnings per share were ₹48.24.

Yes. Glenmark Pharmaceuticals's latest dividend is ₹2.50 per share (250%, final dividend), with an ex-date of 31 Aug 2026. The dividend yield is 0.21%. It has paid 7 dividends in the records shown on this page.

As of Jun 2026: Promoter 46.65%, FII 20.89%, MF 16.76%, Other 15.70%.

Glenmark Pharmaceuticals's listed peers in Biotechnology & Drugs include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Cipla, Zydus Lifesciences. By market capitalisation it ranks #6 of 6 in this group.

No. Glenmark Pharmaceuticals has debt — its debt-to-equity ratio is 0.06 and total debt was ₹594 Cr in FY26.